Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.64 |
| ▸ | JAK3 | P52333 | 5/20 | 0.64 |
| ▸ | KIT | P10721 | 2/20 | 0.61 |
| ▸ | LDLR | P01130 | 1/20 | 0.61 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.61 |
| ▸ | CDC7 | O00311 | 1/20 | 0.53 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 5/20 | 0.52 |
| ▸ | FLT3 | P36888 | 4/20 | 0.52 |
| ▸ | SRC | P12931 | 2/20 | 0.52 |
| ▸ | SYK | P43405 | 2/20 | 0.52 |
| ▸ | PLK4 | O00444 | 2/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.52 |
| ▸ | MARK3 | P27448 | 2/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | BCR | P11274 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27387217 | 1.00 | JAK2 (0.64) | JAK2JAK3KITLDLRPCSK9 | |
| SCHEMBL27387219 | 0.90 | JAK2 (0.77) | JAK2JAK3CDK2PLK4PRKD3 | |
| SCHEMBL27387230 | 0.89 | JAK2 (0.61) | JAK2JAK3KITLDLRPCSK9 | |
| SCHEMBL34463169 | 0.85 | JAK2 (0.65) | JAK2JAK3KITLDLRPCSK9 | |
| SCHEMBL34463164 | 0.82 | KIT (0.61) | JAK2JAK3KITLDLRPCSK9 | |
| SCHEMBL27387032 | 0.80 | JAK2 (0.75) | JAK2JAK3CDK2PLK4PRKD3 | |
| SCHEMBL30788203 | 0.80 | KIT (0.55) | JAK2JAK3KITLDLRPCSK9 | |
| SCHEMBL27387222 | 0.80 | KIT (0.55) | JAK2JAK3KITLDLRPCSK9 | |
| SCHEMBL30788197 | 0.80 | KIT (0.55) | JAK2JAK3KITLDLRPCSK9 | |
| SCHEMBL27387276 | 0.80 | KIT (0.55) | JAK2JAK3KITLDLRPCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103455-A1 | ULK3 INHIBITORS AND USES THEREOF | H LEE MOFFITT CANCER CT & RES (US) | 2026-04-16 | — | — | US | disclosed |
| WO-2024035771-A2 | ULK3 INHIBITORS AND USES THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103455-A1 | ULK3 INHIBITORS AND USES THEREOF | ULK3, ULK1, ULK2 | JAK2 2451/4885JAK3 819/4885KIT 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.